Vaxcyte Stock Performance
| PCVX Stock | USD 75.23 0.86 1.16% |
The entity has a beta of 1.2, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Vaxcyte will likely underperform. At this point, Vaxcyte has a negative expected return of -0.17%. Please make sure to validate Vaxcyte's potential upside and day median price , to decide if Vaxcyte performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Vaxcyte has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors. ...more
Actual Historical Performance (%)
One Day Return 1.14 | Five Day Return 7.46 | Year To Date Return (9.70) | Ten Year Return 187.65 | All Time Return 187.65 |
1 | Acquisition by Elvia Cowan of 7716 shares of Vaxcyte at 25.92 subject to Rule 16b-3 | 12/16/2024 |
2 | Disposition of 280 shares by Guggenhime Andrew of Vaxcyte at 90.241 subject to Rule 16b-3 | 12/18/2024 |
3 | Disposition of 8000 shares by Wassil Jim of Vaxcyte at 2.42 subject to Rule 16b-3 | 01/02/2025 |
4 | Disposition of 125 shares by Eydelman Mikhail of Vaxcyte at 86.52 subject to Rule 16b-3 | 01/06/2025 |
5 | Acquisition by Eydelman Mikhail of 5000 shares of Vaxcyte at 21.41 subject to Rule 16b-3 | 01/07/2025 |
6 | Disposition of 683 shares by Guggenhime Andrew of Vaxcyte at 87.7 subject to Rule 16b-3 | 01/21/2025 |
7 | Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025 | 02/12/2025 |
8 | How Has Vaxcyte Stock Performed Amid Market Fluctuations | 02/25/2025 |
9 | Q4 2024 Vaxcyte Inc Earnings Call Transcript | 02/26/2025 |
10 | Disposition of 2013 shares by Pickering Grant of Vaxcyte at 73.02 subject to Rule 16b-3 | 02/28/2025 |
11 | Vaxcyte, Inc. Among the Cash-Rich Mid Cap Stocks to Buy Now | 03/03/2025 |
12 | Acquisition by Pickering Grant of 57938 shares of Vaxcyte subject to Rule 16b-3 | 03/04/2025 |
13 | Insider Selling Vaxcyte, Inc. COO Sells 8,000 Shares of Stock | 03/05/2025 |
14 | Disposition of 2621 shares by Eydelman Mikhail of Vaxcyte at 70.388 subject to Rule 16b-3 | 03/07/2025 |
| Begin Period Cash Flow | 398.6 M |
Vaxcyte |
Vaxcyte Relative Risk vs. Return Landscape
If you would invest 8,575 in Vaxcyte on December 18, 2024 and sell it today you would lose (1,052) from holding Vaxcyte or give up 12.27% of portfolio value over 90 days. Vaxcyte is currently does not generate positive expected returns and assumes 3.2393% risk (volatility on return distribution) over the 90 days horizon. In different words, 28% of stocks are less volatile than Vaxcyte, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Vaxcyte Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vaxcyte's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Vaxcyte, and traders can use it to determine the average amount a Vaxcyte's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0528
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PCVX |
Estimated Market Risk
| 3.24 actual daily | 28 72% of assets are more volatile |
Expected Return
| -0.17 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Vaxcyte is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vaxcyte by adding Vaxcyte to a well-diversified portfolio.
Vaxcyte Fundamentals Growth
Vaxcyte Stock prices reflect investors' perceptions of the future prospects and financial health of Vaxcyte, and Vaxcyte fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vaxcyte Stock performance.
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.14 | ||||
| Current Valuation | 7.9 B | ||||
| Shares Outstanding | 128.76 M | ||||
| Price To Book | 2.90 X | ||||
| Gross Profit | (75 M) | ||||
| EBITDA | (569.55 M) | ||||
| Net Income | (463.93 M) | ||||
| Cash And Equivalents | 354.5 M | ||||
| Cash Per Share | 5.98 X | ||||
| Total Debt | 71.11 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 11.94 X | ||||
| Book Value Per Share | 26.47 X | ||||
| Cash Flow From Operations | (452.63 M) | ||||
| Earnings Per Share | (3.80) X | ||||
| Market Capitalization | 9.58 B | ||||
| Total Asset | 3.51 B | ||||
| Retained Earnings | (1.39 B) | ||||
| Working Capital | 1.65 B | ||||
About Vaxcyte Performance
Evaluating Vaxcyte's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Vaxcyte has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Vaxcyte has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (45.64) | (47.93) | |
| Return On Tangible Assets | (0.13) | (0.14) | |
| Return On Capital Employed | (0.17) | (0.18) | |
| Return On Assets | (0.13) | (0.14) | |
| Return On Equity | (0.14) | (0.15) |
Things to note about Vaxcyte performance evaluation
Checking the ongoing alerts about Vaxcyte for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vaxcyte help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Vaxcyte generated a negative expected return over the last 90 days | |
| Vaxcyte has high historical volatility and very poor performance | |
| Net Loss for the year was (463.93 M) with loss before overhead, payroll, taxes, and interest of (75 M). | |
| Vaxcyte currently holds about 354.5 M in cash with (452.63 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.98. | |
| Vaxcyte has a frail financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Pickering Grant of 57938 shares of Vaxcyte subject to Rule 16b-3 |
- Analyzing Vaxcyte's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vaxcyte's stock is overvalued or undervalued compared to its peers.
- Examining Vaxcyte's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vaxcyte's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vaxcyte's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vaxcyte's stock. These opinions can provide insight into Vaxcyte's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Vaxcyte Stock Analysis
When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.